4 papers in the library · 92 citations · publishing 2017-2026
Fortschr Neurol Psychiatr June 8, 2026 Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.
[Intravenous Subnarcotic Ketamine Infusions for Treatment-Resistant Depression: Historical Development, Comparison with Esketamine Nasalspray, and Prospects].
Frontiers in Psychiatry 2022 Udo Bonnet, Michael Specka, Ann-Kristin Kanti et al. 4 citations
There is a lack of benefit/harm assessments of illicit and licit psychoactive substances performed by substance-dependent users in comparison to addiction medicine experts. We extended the analyses of substance harm/benefit assessments of German addiction medicine experts (N = 101), in parts reported recently in this journal [doi.org/10.3389/fpsyt.2020.59219], by the perspectives of...
Frontiers in Psychiatry July 7, 2020 Michael Specka, Thomas Kuhlmann, Jürgen Sawazki et al. 42 citations
Background About 15 years ago, a diverse group of new recreational psychotropic substances began to emerge, which were marketed for example as “legal highs,” “research chemicals,” or “designer drugs.” These substances were later subsumed under the label “Novel Psychoactive Substances” (NPS). Important NPS classes are cathinones, synthetic cannabimimetics, phenethylamines, and herbal drugs. The...
Pharmacopsychiatry April 25, 2017 Norbert Scherbaum, Fabrizio Schifano, Udo Bonnet 46 citations
Over the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europe. Apart from some herbal compounds, NPS mainly include synthetic cannabinoids and a range of new synthetic stimulants (e. g., cathinones). Synthetic NPS are often developed whilst modifying the basic chemical (e. g., phenethylamine or tryptamine) structure. Although the pharmacology and...